Home Healthcare Pharmaceuticals Idiopathic Pulmonary Fibrosis Market

Idiopathic Pulmonary Fibrosis Market Size, Share & Trends Analysis Report By Drug Type (Nintedanib, Pirfenidone, Other Drug Types), By Mode of Action (Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes of Action), By End-User (Hospitals and Clinics, Pharmacies, Other end-users) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Idiopathic Pulmonary Fibrosis Market, By Drug Type 2022-2034 (USD MILLION/ Units)
    1. Nintedanib
    2. Pirfenidone
    3. Other Drug Types
  2. Idiopathic Pulmonary Fibrosis Market, By Mode of Action 2022-2034 (USD MILLION/ Units)
    1. Antifibrotic Agents
    2. Tyrosine Kinase Inhibitors
    3. Other Modes of Action
  3. Idiopathic Pulmonary Fibrosis Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Hospitals and Clinics
    2. Pharmacies
    3. Other end-users
  4. Regional Idiopathic Pulmonary Fibrosis Market
    1. North America
      1. North America Idiopathic Pulmonary Fibrosis Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
      2. North America Idiopathic Pulmonary Fibrosis Market By Mode of Action 2022-2034 (USD MILLION/ Units)
        1. Antifibrotic Agents
        2. Tyrosine Kinase Inhibitors
        3. Other Modes of Action
      3. North America Idiopathic Pulmonary Fibrosis Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Clinics
        2. Pharmacies
        3. Other end-users
      4. U.S.
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      5. Canada
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
    2. Europe
      1. Europe Idiopathic Pulmonary Fibrosis Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
      2. Europe Idiopathic Pulmonary Fibrosis Market By Mode of Action 2022-2034 (USD MILLION/ Units)
        1. Antifibrotic Agents
        2. Tyrosine Kinase Inhibitors
        3. Other Modes of Action
      3. Europe Idiopathic Pulmonary Fibrosis Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Clinics
        2. Pharmacies
        3. Other end-users
      4. U.K.
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      5. Germany
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      6. France
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      7. Spain
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      8. Italy
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      9. Russia
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      10. Nordic
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      11. Benelux
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      12. Rest of Europe
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
    3. APAC
      1. APAC Idiopathic Pulmonary Fibrosis Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
      2. APAC Idiopathic Pulmonary Fibrosis Market By Mode of Action 2022-2034 (USD MILLION/ Units)
        1. Antifibrotic Agents
        2. Tyrosine Kinase Inhibitors
        3. Other Modes of Action
      3. APAC Idiopathic Pulmonary Fibrosis Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Clinics
        2. Pharmacies
        3. Other end-users
      4. China
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      5. Korea
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      6. Japan
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      7. India
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      8. Australia
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      9. Singapore
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      10. Taiwan
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      11. South East Asia
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      12. Rest of Asia-Pacific
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
    4. Middle East and Africa
      1. Middle East and Africa Idiopathic Pulmonary Fibrosis Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
      2. Middle East and Africa Idiopathic Pulmonary Fibrosis Market By Mode of Action 2022-2034 (USD MILLION/ Units)
        1. Antifibrotic Agents
        2. Tyrosine Kinase Inhibitors
        3. Other Modes of Action
      3. Middle East and Africa Idiopathic Pulmonary Fibrosis Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Clinics
        2. Pharmacies
        3. Other end-users
      4. UAE
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      5. Turkey
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      6. Saudi Arabia
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      7. South Africa
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      8. Egypt
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      9. Nigeria
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      10. Rest of MEA
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
    5. LATAM
      1. LATAM Idiopathic Pulmonary Fibrosis Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
      2. LATAM Idiopathic Pulmonary Fibrosis Market By Mode of Action 2022-2034 (USD MILLION/ Units)
        1. Antifibrotic Agents
        2. Tyrosine Kinase Inhibitors
        3. Other Modes of Action
      3. LATAM Idiopathic Pulmonary Fibrosis Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Clinics
        2. Pharmacies
        3. Other end-users
      4. Brazil
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      5. Mexico
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      6. Argentina
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      7. Chile
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      8. Colombia
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
      9. Rest of LATAM
        1. Nintedanib
        2. Pirfenidone
        3. Other Drug Types
        4. Antifibrotic Agents
        5. Tyrosine Kinase Inhibitors
        6. Other Modes of Action
        7. Hospitals and Clinics
        8. Pharmacies
        9. Other end-users
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.